subject area of
- Canadian expert consensus: optimal treatment of neovascular age-related macular degeneration Academic Article
- Effectiveness at 1 Year of Monthly versus Variable-Dosing Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-related Macular Degeneration Academic Article
- Efficacy, safety, and treatment burden of treat-and-extend versus alternative anti-VEGF regimens for nAMD: a systematic review and meta-analysis Academic Article
- Genetic Risk Evaluation in Wet Age-Related Macular Degeneration Treatment Response Academic Article
- Genetic Risk Factors Are Not Associated with Wet Age-Related Macular Degeneration Treatment Response to Ranibizumab Academic Article
- IMPACT OF FLUID COMPARTMENTS ON FUNCTIONAL OUTCOMES FOR PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION Academic Article
- Imaging Biomarkers and Their Impact on Therapeutic Decision-Making in the Management of Neovascular Age-Related Macular Degeneration Academic Article
- MANAGEMENT OF RETINAL PIGMENT EPITHELIUM TEAR DURING ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY Academic Article
- Ozurdex in age-related macular degeneration as adjunct to ranibizumab (The OARA Study) Academic Article
- Pharmacologic management of neovascular age-related macular degeneration: systematic review of economic evidence and primary economic evaluation Academic Article
- Ranibizumab and the eye Academic Article
- Ranibizumab vs. aflibercept for wet age-related macular degeneration: network meta-analysis to understand the value of reduced frequency dosing Academic Article
- SUSPENDING TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN CASES OF FUTILITY Academic Article